Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cortex (Cor) [formerly CORX] -- Ignore unavailable to you. Want to Upgrade?

To: daveG who wrote (805)	4/19/1999 9:32:00 AM
From: daveG	Read Replies (1) \| Respond to of 1255

Cortex Pharmaceuticals' Experimental Drug for Schizophrenia Shows Statistically Significant Effects in Cognition Improvement Results Exceeded Our Expectations' SANTA FE, N.M., April 18 /PRNewswire/ -- In a presentation at the International Congress on Schizophrenia Research today, Donald C. Goff, M.D., principal investigator, reported results of a clinical trial with CX516 (Ampalex(R)) in 19 patients with schizophrenia. Dr. Goff is Director of the Psychotic Disorders Program at Massachusetts General Hospital in Boston. The double blind, placebo-controlled four-week study is intended to evaluate the safety of combining CX516 (Ampalex) with clozapine, a commonly used anti-psychotic medication. CX516 (Ampalex) is one of the new Ampakine(R) class of drugs being developed by Cortex Pharmaceuticals, Inc. (OTC Bulletin Board: CORX). Dr. Goff reported that Ampalex was well tolerated and did not induce any significant adverse effects. "Ampalex appears to have improved a number of aspects of cognitive function as measured by a battery of neuropsychiatric tests," stated Dr. Goff. "Patients receiving the drug exhibited improvements in performance on tests of verbal learning and memory, problem solving, and distractibility. The magnitude of improvement in the California Verbal Learning Test was particularly impressive. This test is an excellent predictor of the ability of patients to return to normal function." ......more....